McKesson and CD&R agree $5.8 bn acquisition of Option Care Health
McKesson Corp. and private‑equity firm Clayton, Dubilier & Rice have signed an agreement to acquire Option Care Health. The transaction values the home‑infusion provider at an enterprise value of about $5.8 bn, or $32.05 per share. McKesson will invest roughly $1.4 bn for a 49 % stake while CD&R will take the majority 51 % interest. The deal is slated to close in the first half of 2027 and will take Option Care private, ending its Nasdaq listing.
Why it matters
The acquisition expands McKesson’s specialty‑care platform into home and outpatient infusion services, a growing segment of drug delivery. Analysts note that the added service business could improve margins compared with pure drug distribution. Option Care’s shareholders will receive cash at $32.05 per share and the company will cease to be publicly traded.
Key facts
- 1The enterprise value of the transaction is near $5.8 bn. briefs.co
- 2The price per share is $32.05. briefs.co
- 3McKesson will invest about $1.4 bn for a 49 % ownership stake. briefs.co
- 4CD&R will hold a 51 % controlling interest. managedhealthcareexecutive.com
- 5The deal is expected to close in the first half of 2027. healthcare-digital.com
- 6Option Care Health will be delisted from Nasdaq and become a private company. managedhealthcareexecutive.com
Open questions
- Material 4 cites a 37 % premium to the prior close, while material 5 cites a 36 % premium.
Summary written by AlphAI from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.